KraneShares CSI China Internet ETF vs Vaxcyte Inc. Common Stock — how do they compare? KraneShares CSI China Internet ETF trades at $24.14 (market cap $4.51B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 2.3× KraneShares CSI China Internet ETF's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 59 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| KWEB | PCVX | |
|---|---|---|
Market Cap | $4.51B | $10.51B |
Volume | 12,272,723 | 2,644,694 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $73.82 |
52-Week Low | $23.63 | $40.32 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | — | $9.14B |
Signals from Pluang's Aura AI — not financial advice
KWEB trades at $24.72, down 0.12% with neutral technical signals. The ETF faces mixed institutional activity amid ongoing U.S.-China trade dynamics. Recent news highlights China's economic challenges including industrial overcapacity and trade rebalancing pressures, while corporate profits showed a 26% Q2 surge according to Zacks Investment Research on September 8, 2026.
The outlook remains cautious due to geopolitical tensions and China's economic headwinds. Investment opportunity exists if U.S.-China relations improve, but risks include trade protectionism and domestic consumption weakness. Technical indicators suggest limited near-term momentum with key support at $25.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →